Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus
- 8 January 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (3) , 236-240
Abstract
Aims: To compare the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 diabetes mellitus ( T1DM ) versus type 2 diabetes mellitus ( T2DM ) in order to explore the potential of dapagliflozin as add‐on therapy to insulin in patients with T1DM . Methods: Steady‐state pharmacokinetics and pharmacodynamics of dapagliflozin (1–100 mg) were evaluated in a meta‐analysis of patients with T1DM or T2DM . A model was constructed of the relationship between dapagliflozin systemic exposure and urinary glucose excretion ( UGE ) in patients with T1DM versus those with T2DM . Results: Data were analysed from 160 patients ( T1DM , n = 70; T2DM , n = 90). Dapagliflozin systemic exposure (maximum concentration and area under the curve) increased similarly in a dose‐related manner in both patient populations. Dose‐dependent increases in 24‐h UGE were observed with dapagliflozin in both populations. Unadjusted results showed that with regard to UGE response, dapagliflozin was more potent in patients with T1DM {mean half‐maximum effective concentration [ EC 50 ] = 2.72 ng/ml [95% confidence interval ( CI ) 1.14, 5.08]} than in patients with T2DM [ EC 50 = 12.2 ng/ml (95% CI 4.91, 21.1)]. After normalization for baseline fasting plasma glucose, estimated glomerular filtration rate and UGE , however, the UGE potency of dapagliflozin was similar between the two populations [ T1DM : mean EC 50 , 8.12 ng/ml (95% CI 2.95, 14.6); T2DM : mean EC 50 , 7.75 ng/ml (95% CI 1.35, 18.1)]. Conclusions: Dapagliflozin pharmacokinetics and the predicted UGE dose exposure response to dapagliflozin were similar in patients with T1DM and those with T2DM and suggest that the dapagliflozin dosages currently used for the treatment of T2DM may provide benefit as add‐on therapy to insulin in patients with T1DM .Keywords
Funding Information
- AstraZeneca
- Bristol-Myers Squibb
This publication has 20 references indexed in Scilit:
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2Clinical Pharmacokinetics, 2013
- Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 yearsDiabetes, Obesity and Metabolism, 2013
- Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic RegistryThe Journal of Clinical Endocrinology & Metabolism, 2013
- Pharmacotherapy in Type 1 DiabetesCanadian Journal of Diabetes, 2013
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of InsulinAnnals of Internal Medicine, 2012
- Strategies to Limit the Effect of Hypoglycemia on Diabetes Control: Identifying and Reducing the RisksClinical Diabetes, 2012
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2011
- Adherence challenges in the management of type 1 diabetes in adolescents: prevention and interventionCurrent Opinion in Pediatrics, 2010
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy SubjectsClinical Pharmacology & Therapeutics, 2009
- Insulin‐associated weight gain in diabetes – causes, effects and coping strategiesDiabetes, Obesity and Metabolism, 2006